Cartesian Therapeutics products
Selecta Biosciences ImmTOR - Immune Tolerance Platform
Selecta Biosciences’ immune tolerance platform, ImmTOR, is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses.
ImmTOR - Model SEL-212 - Enzymatic Therapy
Building upon the proven success of SEL-212, ImmTOR has exciting potential to give rise to antigen-specific immunity across a range of immunogenic compounds when co-administered with biologic therapies like enzymes.
ImmTOR in Gene Therapy
ImmTOR has significant potential to mitigate unwanted immune responses and induce AAV-specific tolerance to enable redosing of gene therapies. ImmTOR has the potential to administer multiple low doses to achieve therapeutic benefit without risk of overdosing, the ability to treat patients typically excluded from these treatments and is a novel approach to treating systemic diseases resulting from genetic disorders.
Autoimmune Therapies
The current standard of care for autoimmune diseases is broad immunosuppression, which is associated with side effects and leaves patients vulnerable to serious infection and maligancies. Our approach to autoimmune disease is designed to restore natural self-tolerance by administering ImmTOR with nanoparticles-encapsulated self-antigens and avoid the need for chronic and systemic immune suppression.
ImmTOR + Gene Therapy Program
Model MMA-101 - ImmTORTM + Gene Therapy Candidate for Methylmalonic Acidemia (MMA)
Selecta’s first ImmTORTM + gene therapy candidate MMA-101 for methylmalonic acidemia (MMA) is expected to enter clinical trials the end of 2021. MMA is a rare metabolic disease that may lead to metabolic acidosis and hyperammonemia and is associated with long-term complications including feeding problems, developmental delay, intellectual disability, and chronic kidney disease.
Model SEL-313 - Gene Therapy Program for the Treatment of Ornithine Transcarbamylase (OTC)
Selecta’s wholly owned gene therapy program for the treatment of ornithine transcarbamylase (OTC) deficiency is expected to enter the clinic in 2022. OTC deficiency is a genetic disorder urea cycle that causes ammonia to accumulate in the blood. The most severe form of the disorder presents within the first few days of life. Severe symptoms include inability to control body temperature and breathing rate, seizures, coma, developmental delays, and intellectual disability. Less severe forms of the disorder are characterized by delirium, erratic behavior, aversion to high protein foods, vomiting and seizures.